Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 17/20 | 0.49 |
| ▸ | SRC | P12931 | 13/20 | 0.49 |
| ▸ | XDH | P47989 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17313640 | 1.00 | ABL1 (0.49) | ABL1SRCXDHMEN1POLB | |
| SCHEMBL15859944 | 0.84 | ABL1 (0.46) | ABL1SRCXDH | |
| SCHEMBL17313624 | 0.84 | ABL1 (0.46) | ABL1SRCXDH | |
| SCHEMBL17313590 | 0.82 | ABL1 (0.48) | ABL1SRCXDHMEN1POLB | |
| SCHEMBL17313591 | 0.82 | ABL1 (0.48) | ABL1SRCXDHMEN1POLB | |
| SCHEMBL17311265 | 0.81 | ABL1 (0.67) | ABL1SRCXDH | |
| SCHEMBL17313583 | 0.78 | ABL1 (0.48) | ABL1SRCXDH | |
| SCHEMBL17313582 | 0.78 | ABL1 (0.48) | ABL1SRCXDH | |
| SCHEMBL17313579 | 0.77 | ABL1 (0.48) | ABL1SRC | |
| SCHEMBL15859942 | 0.77 | ABL1 (0.48) | ABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
| US-9006457-B2 | Reactive ionic liquids | BASF SE (DE) | 2015-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | MAP2K2, MAP2K5, MAP2K3 | ABL1 68/4885SRC 284/4885XDH 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.